- Author:
Hamdy ABDEL AZIM
1
;
Loay KASSEM
;
Kyrillus Samaan SHOHDY
;
Boules ESHAAK
;
Shady Elia ANIS
;
Nermine Shawky KAMAL
Author Information
- Publication Type:Case Report
- Keywords: Luteinizing hormone-releasing hormone; Androgen receptor; Triple-negative breast neoplasms
- MeSH: Breast Neoplasms, Male; Drug Therapy; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Lutein; Male; Male; Rare Diseases; Receptors, Androgen; Triple Negative Breast Neoplasms
- From:Journal of Breast Cancer 2019;22(1):141-148
- CountryRepublic of Korea
- Language:English
- Abstract: The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of this strategy in male patients with TNBC. In this report, we describe a male patient with AR-positive TNBC who was successfully treated using an LHRH agonist after pretreatment with several lines of chemotherapy and achieved a durable response. We also review the existing evidence supporting LHRH- and AR-targeted therapy for this rare disease.